logo-loader
ASX:ATX OTCQB:INNMF

Amplia Therapeutics Ltd

Receive alerts
Market:
ASX
Price
0.08 AUD
Day Change
-2.47%
Market Cap:
$40.55 m
52 weeks high
0.28
52 weeks low
0.08

In brief

Amplia Therapeutics Limited is an Australian, clinical-stage, drug development company focused on the development of two potent, orally-available inhibitors of Focal Adhesion Kinase (FAK) for the treatment of cancer and fibrotic diseases.​

The first of these drugs, narmafotinib (AMP945), is a highly selective and potent inhibitor of FAK and is currently in a phase 2 clinical trial for pancreatic cancer, in clinical development for ovarian cancer, and advanced preclinical development for idiopathic pulmonary fibrosis (IPF).